Format

Send to

Choose Destination
Ann Am Thorac Soc. 2014 Aug;11 Suppl 4:S201-10. doi: 10.1513/AnnalsATS.201401-036PL.

Challenges and future in vaccines, drug development, and immunomodulatory therapy.

Author information

1
1 Department of Immunology.

Abstract

Pulmonary diseases and infections are among the top contributors to human morbidity and mortality worldwide, and despite the successful history of vaccines and antimicrobial therapeutics, infectious disease still presents a significant threat to human health. Effective vaccines are frequently unavailable in developing countries, and successful vaccines have yet to be developed for major global maladies, such as tuberculosis. Furthermore, antibiotic resistance poses a growing threat to human health. The "Challenges and Future in Vaccines, Drug Development, and Immunomodulatory Therapy" session of the 2013 Pittsburgh International Lung Conference highlighted several recent and current studies related to treatment and prevention of antibiotic-resistant bacterial infections, highly pathogenic influenza, respiratory syncytial virus, and tuberculosis. Research presented here focused on novel antimicrobial therapies, new vaccines that are either in development or currently in clinical trials, and the potential for immunomodulatory therapies. These studies are making important contributions to the areas of microbiology, virology, and immunology related to pulmonary diseases and infections and are paving the way for improvements in the efficacy of vaccines and antimicrobials.

KEYWORDS:

antimicrobials; influenza vaccines; respiratory syncytial virus; tuberculosis

PMID:
25148426
PMCID:
PMC4200570
DOI:
10.1513/AnnalsATS.201401-036PL
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center